Use of Tissue Specimens from Stereotactic Biopsies for Patient-Derived GBM Organoid-Based Drug Testing
Cells · 12.05.2025 · 14 (10) · 701
DOI: 10.3390/cells14100701 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 12.05.2025. Verfasst von Amélie Wöllner und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Experimental Neurosurgery, Department of Neurosurgery, Medical Faculty of Heidelberg, University of Heidelberg, 69120 Heidelberg, Germany. Hauptthemen laut MEDLINE: Organoids, Glioblastoma, Brain Neoplasms, Stereotaxic Techniques. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dietmar Hopp Stiftung, Deutsche Forschungsgemeinschaft, Dietmar Hopp Foundation.
Abstract (Originalsprache)
IDH-wildtype glioblastoma (GBM) represents the most common malignant form of brain tumor and is still incurable despite comprehensive therapeutic efforts. Due to tumor location and patient condition, open surgical resection of recurrent GBM is not always feasible. In these cases, frame-based stereotactic biopsies represent a less invasive technique to obtain tissue samples for diagnostics. However, whether this material would also be sufficient to prepare tumor organoids (TOs) and perform drug screenings has not been addressed so far. In this study, we present our highly optimized workflow for generating standardized patient-derived GBM TOs from single-cell suspensions using limited biopsy-derived material. We highlight crucial steps within the procedure, such as reliable cell counting, viable cell recovery, enzymatic digestion, and the requirement of an extracellular matrix as a scaffold. Furthermore, we showcase the potential of personalized drug testing as a promising application of GBM TOs. In conclusion, we successfully developed a robust workflow that effectively utilizes the limited material derived from stereotactic biopsies to reproducibly form standardized TOs. Moreover, we demonstrate that biopsy-derived TOs represent a valuable tool for testing drug vulnerabilities in a personalized setting, which might be especially useful in the case of non-resectable GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Experimental Neurosurgery, Department of Neurosurgery, Medical Faculty of Heidelberg, University of Heidelberg, 69120 Heidelberg, Germany.
- Department of Neuropathology, Medical Faculty of Heidelberg, University of Heidelberg, 69120 Heidelberg, Germany.
- Division for Stereotactic Neurosurgery, Department of Neurosurgery, Medical Faculty of Heidelberg, University of Heidelberg, 69120 Heidelberg, Germany.
ORCID-Profile: Amélie Wöllner, Catharina Lotsch, Gerhard Jungwirth, Lena Jassowicz, Martin Jakobs, Rolf Warta, Christel Herold-Mende
Förderung
- Dietmar Hopp Stiftung
- Deutsche Forschungsgemeinschaft
- Dietmar Hopp Foundation
Zitieren
APA
Wöllner, A., Paul, A., Arquilla, M., Cao, J., Lotsch, C., Jungwirth, G., Jassowicz, L., von Deimling, A., Unterberg, A. W., Krieg, S. M., Jakobs, M., Warta, R., & Herold-Mende, C. (2025). Use of Tissue Specimens from Stereotactic Biopsies for Patient-Derived GBM Organoid-Based Drug Testing. Cells, 14(10), 701. https://doi.org/10.3390/cells14100701
Vancouver
Wöllner A, Paul A, Arquilla M, Cao J, Lotsch C, Jungwirth G, et al. Use of Tissue Specimens from Stereotactic Biopsies for Patient-Derived GBM Organoid-Based Drug Testing. Cells. 2025;14(10):701. doi:10.3390/cells14100701
BibTeX
@article{Wllner2025,
author = {Wöllner, Amélie and Paul, Adrian and Arquilla, Maddalena and Cao, Junguo and Lotsch, Catharina and Jungwirth, Gerhard and Jassowicz, Lena and von Deimling, Andreas and Unterberg, Andreas W and Krieg, Sandro M and Jakobs, Martin and Warta, Rolf and Herold-Mende, Christel},
title = {Use of Tissue Specimens from Stereotactic Biopsies for Patient-Derived GBM Organoid-Based Drug Testing},
journal = {Cells},
year = {2025},
volume = {14},
number = {10},
pages = {701},
doi = {10.3390/cells14100701}
}
EUVIMED